Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers

Eshan U. Patel(Johns Hopkins University), Evan M. Bloch(Johns Hopkins University), William Clarke(Johns Hopkins University), Yu‐Hsiang Hsieh(Johns Hopkins University), Denali Boon(Johns Hopkins University), Yolanda Eby(Johns Hopkins University), Reinaldo E. Fernández(Johns Hopkins University), Owen R. Baker(National Institutes of Health), Morgan Keruly(Johns Hopkins University), Charles Kirby(Johns Hopkins University), Ethan Klock(Johns Hopkins University), Kirsten Littlefield(Johns Hopkins University), Jernelle Miller(Johns Hopkins University), H Schmidt(Johns Hopkins University), Philip A. Sullivan(Johns Hopkins University), Estelle Piwowar‐Manning(Johns Hopkins University), Ruchee Shrestha(Johns Hopkins University), Andrew D. Redd(National Institutes of Health), Richard E. Rothman(Johns Hopkins University), David Sullivan(Johns Hopkins University), Shmuel Shoham(Johns Hopkins University), Arturo Casadevall(Johns Hopkins University), Thomas C. Quinn(National Institutes of Health), Andrew Pekosz(Johns Hopkins University), Aaron A.R. Tobian(Johns Hopkins University), Oliver Laeyendecker(National Institutes of Health)
Journal of Clinical Microbiology
November 3, 2020
10.1128/jcm.02257-20
Cited by 198Open Access
Full Text

Abstract

Accurate serological assays to detect antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to characterize the epidemiology of SARS-CoV-2 infection and identify potential candidates for coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) donation. This study compared the performances of commercial enzyme immunoassays (EIAs) with respect to detection of IgG or total antibodies to SARS-CoV-2 and neutralizing antibodies (nAbs). The diagnostic accuracy of five commercially available EIAs (Abbott, Euroimmun, EDI, ImmunoDiagnostics, and Roche) for detection of IgG or total antibodies to SARS-CoV-2 was evaluated using cross-sectional samples from potential CCP donors who had prior molecular confirmation of SARS-CoV-2 infection ( n = 214) and samples from prepandemic emergency department patients without SARS-CoV-2 infection ( n = 1,099).

Related Papers

No related papers found

Powered by citation graph analysis